Redsense Medical AB postpones the Annual General Meeting in an effort to contribute to social distancing and reduce the impact of the COVID-19 outbreak
The Board of Directors of Redsense Medical AB has resolved to postpone the Annual General Meeting of shareholders. The event will be held on Monday, 22 June 2020, 16:30, instead of 4 May 2020 as previously disclosed. Further information about the meeting will be announced at a later time.
The publication dates for financial information are not affected by this decision and remain unchanged. The Company’s Q1 report will be issued on 4 May 2020 as planned.
Redsense’s decision to postpone the AGM stems from the Company’s ambition to do what it can to curb the spread of the coronavirus, and hopefully make it possible for shareholders to meet the Company’s management under less difficult circumstances.
“In these times, communities are being asked to refrain from gatherings when it can be avoided, and citizens are being asked to limit their interaction when possible and to maintain social distancing to protect groups at risk. The coronavirus poses a serious threat and we want to contribute to slowing its spread to the best of our ability,” says Redsense Medical’s CEO Patrik Byhmer: “Our company is literally built on the vision to improve care and save lives, and our foremost priority right now is the well-being of our staff, partners and investors; we want to give our shareholders a chance to come together with each other and the company’s representatives under the best possible circumstances. We believe that a postponement currently is the best way to achieve that.”
For more information, please contact:
Patrik Byhmer, CEO Redsense Medical AB (publ)
Phone: +46 35 10 60 30
ABOUT REDSENSE MEDICAL
Redsense Medical is a corporate group with operations mainly in Europe and the United States. The company has developed the Redsense System, an innovationused for monitoring and alarm in the case of blood leakage in connection with a hemodialysis treatment. Redsense Medical solves one of the most serious remaining safety problems within hemodialysis – to quickly detect Venous Needle Dislodgement and catheter leakage to minimize blood leakage. The system consists of a patented fiber optic sensor, designed for either venous needle or central venous catheter, which is connected to an alarm unit. From the very start, the development of the company's technology has been based on the demands and safety requirements of healthcare providers in the dialysis sector.